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TO THE EDITOR
The incidence of nonmelanoma skin
cancer (NMSC) increases worldwide,
partly due to the population ageing.
Therefore, any impact of NMSC on
mortality would have major public
health implications. Data on mortality
after NMSC are few and remain contro-
versial and the role of co-morbidity has
not been clarified.
We therefore assessed the associa-
tion between NMSC in Denmark and
mortality throughout a 10-year follow-
up period, and compared with that of
a reference cohort from the general
population.
This nationwide cohort of NMSC
was created in 1995. Data were col-
lected from patients’ clinical records
collected by all Danish dermatologists,
and pathological records collected by
the collaborating dermatopathologists.
In 1995, Denmark had 5,227,861
inhabitants, and the entire population
received tax-supported free health care
from the National Health Service.
Clinical and pathological records
were available for 3,209 patients with
an incident diagnosis of NMSC, while
2,759 patients only had pathological
records (Table 1). Incident cases of
NMSC were determined by record
linkage to the Danish Cancer Registry
(Storm et al., 1997). This linkage was
obtained by the unique 10-digit civil
registration number, assigned to all
Danish residents by the Civil Registra-
tion System, which allows unambigu-
ous record linkage between registries.
The Civil Registration System, which
has existed since 1968, is updated
daily and contains information on vital
status, civil status, date of death, and
the residence. Through this, a reference
cohort of 10 persons for each NMSC
patient matched on age, gender, and
municipality (31,729 persons) was
sampled from the general population.
Likewise, mortality, civil status, and
migration data for both cohorts were
obtained from the Civil Registration
System. For the patients, the follow-up
period began at the date of diagnosis;
for the reference cohort, it began at the
date when their corresponding patient
was diagnosed (index date) and for both
groups it ended at the date of emigra-
tion, death, or on 1 November 2004,
whichever occurred first. The under-
lying cause of death was retrieved
from the death certificates stored in
the National Board of Health (Juel and
Helweg-Larsen, 1999).
We computed the Charlson Co-
morbidity Index (Charlson et al., 1987)
based on all hospital discharge diag-
noses in the National Patient Registry
established 1 January 1977, until
the diagnosis date of each patient and
index date of each reference. As a
measure of socio-economic position,
we defined three levels of civil status as
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Table 1. Characteristics of the included and excluded cohort of
nonmelanoma skin cancer patients (the Gerda Frentz data)




Age (years)1 69 (18–99) 68 (19–100)
Male/female 1:1 1:1
No. of incident BCC 3,019 2,436 BCC
2,120 Nodular and ulcerative BCC —
791 superficial BCC —
97 schlerodermic BCC —
11 multiple carcinomas —
No. of incident SCC 190 323 SCC
116 SCC —
74 Bowens disease —
BCC:SCC ratio 26:1 8:1
Crude MRR2 (exclusion analysis) 0.91 (95% CI 0.86–0.97) 1.00 (95% CI 0.93–1.06)
Person years of follow-up 58,699 (patients) 59,089 (patients)
201,306 (references) 165,034 (references)
Number of deaths during follow-up 1,140 (patients) 1,121 (patients)
12,134 (references) 11,022 (references)
BCC, basal cell carcinoma; CI, confidence interval; MRR, mortality rate ratio; SCC, squamous cell
carcinoma.
1Median (range).
2The MRR and associated 95% CI of patients compared with references were computed using Cox’s
regression.
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; MRR, mortality rate ratio;
NMSC, nonmelanoma skin cancer; SCC, squamous cell carcinoma.
of the diagnosis date and the index
date: married, not married, and un-
known (records of civil status were
unknown for 20% of both cohorts).
We used Cox’s regression analysis to
estimate the mortality rate ratio (MRR)
between patients with NMSC and the
reference cohort with associated 95%
confidence interval (CI), adjusting for
co-morbidity and civil status.
Among patients with nodular and
ulcerative basal cell carcinoma (BCC),
the adjusted MRR was 0.88 (95% CI,
0.81–0.94), for patients with superficial
BCC 0.69 (95% CI, 0.60–0.81) and for
patients with sclerodermic BCC 1.01
(95% CI, 0.71–1.42). The adjusted
MRR for patients with squamous cell
Table 2. Cause-specific mortality among patients with NMSC and references1
10 year follow-up (1995–2004)
BCC causes of death (ICD-10) N Mortality rate/100 person-years (95% CI) MRR2 95% CI
Overall mortality
References 11,087 4.97 (4.87–5.06) 1.0 (ref) —
Patients 1,019 4.40 (4.14–4.68) 0.89 0.83–0.95
Heart disease
References 2,705 1.21 (1.16–1.25) 1.0 (ref) —
Patients 243 1.04 (1.00–1.18) 0.86 0.75–0.99
Vascular disease of the circulatory system
References 673 0.30 (0.28–0.32) 1.0 (ref) —
Patients 45 0.19 (0.14–0.26) 0.64 0.47–0.87
Gastrointestinal disease, other than cancer
References 476 0.21 (0.19–0.23) 1.0 (ref) —
Patients 28 0.12 (0.08–0.17) 0.57 0.37–0.83
Other malignant disease, except skin cancer
References 2,464 1.10 (1.06–1.14) 1.0 (ref) —
Patients 257 1.10 (1.00–1.25) 1.01 0.88–1.14
Malignant melanoma
References 28 0.01 (0.01–0.02) 1.0 (ref) —
Patients 8 0.03 (0.02–0.07) 2.75 1.08–6.20
10 year follow-up (1995–2004)
SCC causes of death (ICD-10) N Mortality rate/100 person-years (95% CI) MRR2 95% CI
Overall mortality
References 661 9.21 (8.54–9.94) 1.0 (ref) —
Patients 86 14.9 (12.0–18.4) 1.61 1.27–2.02
Heart disease
References 171 2.38 (2.05–2.76) 1.0 (ref) —
Patients 23 3.97 (2.64–5.97) 1.71 1.05–2.65
Bronchitis, emphysema, and asthma
References 31 0.43 (0.30–0.61) 1.0 (ref) —
Patients 5 0.86 (0.36–2.08) 2.00 0.61–5.19
Gastrointestinal disease, other than cancer
References 32 0.44 (0.31–0.63) 1.0 (ref) —
Patients 4 0.69 (0.26–1.84) 1.55 0.40–4.38
Other malignant disease, except skin cancer
References 84 1.17 (0.94–1.45) 1.0 (ref) —
Patients 11 1.90 (1.05–3.43) 1.63 0.78–3.06
BCC, basal cell carcinoma; CI, confidence interval; MRR, mortality rate ratio; NMSC, nonmelanoma skin cancer; SCC, squamous cell carcinoma.
1We included categories of the underlying cause of death with relevant differences between patients and references.
2The MRR and associated 95% CI of patients compared with references was computed by direct calculation of the Incidence Rate Ratio.
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carcinoma (SCC) was 1.32 (95% CI,
1.05–1.65), for patients with Bowen
disease 0.70 (95% CI, 0.50–1.01), and
for patients with multiple carcinoma
0.53 (95% CI, 0.12–2.42). We further
stratified the patients into subgroups
according to anatomic distribution of
the carcinomas. We found a reduced
mortality among patients with BCC
located on the trunk for nodular and
ulcerative BCC (adjusted MRR¼0.79
(95% CI, 0.63–0.99)) and for superficial
BCC located on the extremities (ad-
justed MRR¼ 0.60 (95% CI, 0.39–
0.91)). No substantial difference was
found for SCC patients according to
anatomic distribution of the carcinomas.
For patients with BCC, overall,
cardiovascular, and gastrointestinal dis-
ease mortality was reduced, while
mortality from other malignant diseases
was increased compared with the
references (Table 2). The overall and
cause-specific mortality was higher
among patients with SCC with an
increased mortality from heart disease,
lung, gastrointestinal, and other malig-
nant diseases.
Our findings indicate that BCC may
improve life expectancy, which seems
unlikely. Thus, recent biological studies
suggest that solar radiation, which is
associated with NMSC, might have a
beneficial effect on the prognosis of a
number of fatal diseases (Hughes et al.,
2004; Berwick et al., 2005).
The association is more likely due to
selection bias, if the members of the
cohort of BCC patients included differ
from the BCC patients not included (the
patients included in this study needed
to be able to consult a dermatologist in
private practice). The 2,759 patients
excluded because of the absence
of clinical records (recorded only by
the dermatopathologists) had the same
mortality as their reference cohort,
presumably because of a higher relative
number of SCC patients in this cohort
(Table 1). We found a reduction in
cause-specific mortality of smoking-
related and gastrointestinal diseases
among patients with BCC, which could
be reflected by the selection of a
healthy cohort of patients diagnosed
with BCC, or by these factors being
‘‘protective’’ for BCC. The reduction in
total and cause-specific mortality of
smoking-related and gastrointestinal
diseases was not found for SCC patients
in our study, indicating that selection
bias might not be present.
The patients in our study cohort
were seen by a dermatologist, and all
cases were ascertained with a histo-
logical diagnosis performed by a der-
matopathologist. Therefore, we would
expect a high diagnostic accuracy.
Co-morbidity and socio-economic
position, for which we adjusted, are
known to have an impact on mortality
(Yancik et al., 1998; Galobardes et al.,
2006). However, there may be some
residual confounding from co-morbid-
ity and socio-economic position since
measurements of these factors were not
complete (Extermann, 2000). Unmea-
sured confounding factors may be
present (life style factors) and the
differences of these factors between
patients and the reference cohort may
have influenced our results.
In contrast to our study, no differ-
ence has been shown in relative mor-
tality among patients compared with
the general population in the few
mortality studies of NMSC (Karjalainen
et al., 1989; Kahn et al., 1998; Lewis
and Weinstock, 2004). Since selection
bias cannot be excluded, a study
considering the whole cohort of
NMSC patients in 1995 is needed
to quantify an unbiased association
between NMSC and mortality.
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